2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 492

Patient-Reported Outcomes from a Canadian Study of Patients Taking Methotrexate and Etanercept
Abstract Number: 289

Patient-Reported Outcomes in Children with Moderately to Severely Active Polyarticular or Polyarticular-Course Juvenile Idiopathic Arthritis Who Are Prescribed and Treated with Adalimumab
Abstract Number: 2520

Patient, Genetic and Disease Factors Influence the Response to the Disease Modifying Anti-Rheumatic Drug Leflunomide
Abstract Number: 2971

Patient’s Self-Monitoring Via Smartphone: The Compass Study Correlation Between Patient Self-Assessment of Rheumatoid Arthritis Disease Activity Via Smartphone Technology and Physicians’ Validated Scores
Abstract Number: 1881

Patients Who Fail Biologics Are More Likely to Have Concomitant Fibromyalgia
Abstract Number: 1466

Patients with Active Rheumatoid Arthritis Display an Expanded Population of GM-CSF Expressing Peripheral B Cells
Abstract Number: 579

Patients with Ankylosing Spondylitis Do Not Adapt to Their Disease: Evidence from the ‘then Test’ in Patients Treated with TNF-Inhibitors
Abstract Number: 2135

Patients with Moderate Disease Activity in the First 5 Years of Rheumatoid Arthritis Still Progress Radiographically Despite Conventional Disease Modifying Therapy
Abstract Number: 2593

Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis Demonstrate the Same Clinical Disease Course over Two Years: Results from the Gespic Cohort
Abstract Number: 589

Patients with Nr-Axspa Show a Statistically Higher Disease Burden in Clinical Practice Compared with Patients with Radiographic Axial Spa
Abstract Number: 1274

Patients with Osteoarthritis Do NOT Have Increased Risk of Cardiovascular Disease in Ullensaker Community in Norway
Abstract Number: 1059

Patients with RA from Wealthier Countries Perform Better on Clinical Disease Activity Measures, but Tend to Show Worse Person Reported Outcomes
Abstract Number: 2721

Patients’ Perspective of Skin Involvement in Systemic Sclerosis
Abstract Number: 2386

Patients’ Interpretations of Rheumatoid Arthritis Model Disease States in a Safety-Net Rheumatology Clinic
Abstract Number: 290

Patterns of Active Joint Involvement in JIA

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].